Nxera Pharma to Receive US$10 Million Milestone Payment from AbbVie under Collaboration Targeting Neurological Diseases
September 29, 2025 19:30 ET Â | Source: Nxera Pharma Tokyo, Japan and…
EverBridge Group and Cosmotec Forge Landmark Partnership
SHANGHAI, Sept. 15, 2025 /PRNewswire/ -- EverBridge Group announced an Exclusive Commercialization…
Nxera Pharma and Cancer Research UK Announce First Patient Dosed in Phase 2a Trial of Investigational Cancer Immunotherapy HTL0039732
HTL0039732 (also known as NXE0039732) is Nxera’s novel oral EP4 antagonist being…
MiTAC Computing Partners with Industry Leaders on Open AI Server Solutions at OCP APAC Summit 2025
TAIPEI, Aug. 7, 2025 /PRNewswire/ -- MiTAC Computing Technology Corporation, a leading…
Kyowa Kirin Announces Abstract Presentation at the European Academy of Dermatology and Venereology (EADV) Congress
PRINCETON, N.J. and TOKYO, July 29, 2025 /PRNewswire/ -- Kyowa Kirin Co.,…
Nxera Pharma to Receive US$4.8 Million in Milestone Payments Following Centessas Initiation of Clinical Development of ORX142, a Novel Orexin Receptor 2 (OX2R) Agonist
July 04, 2025 03:00 ET Â | Source: Nxera Pharma Tokyo, Japan and…